Special Issue "Drug Interactions of Antimicrobial Agents"

Quicklinks

A special issue of Pharmaceutics (ISSN 1999-4923).

Deadline for manuscript submissions: closed (31 May 2011)

Special Issue Editor

Guest Editor
Dr. Federico Pea

Institute of Clinical Pharmacology and Toxicology, University Teaching Hospital of Udine, P.le SM Misericordia, 3, 33100 Udine, Italy
Interests: chemotherapy (especially on clinical pharmacokinetics and optimization of antimicrobial therapy in critically ill patients); clinical pharmacology; pharmacokinetics; drug interactions; pharmacodynamics

Keywords

  • cytochrome P450
  • P-glycoprotein
  • inhibition
  • induction
  • antimicrobial agents

Published Papers (2 papers)

View options order results:
result details:
Displaying articles 1-2
Export citation of selected articles as:

Review

Open AccessReview Pharmacokinetic Drug Interactions of Antimicrobial Drugs: A Systematic Review on Oxazolidinones, Rifamycines, Macrolides, Fluoroquinolones, and Beta-Lactams
Pharmaceutics 2011, 3(4), 865-913; doi:10.3390/pharmaceutics3040865
Received: 15 October 2011 / Revised: 26 October 2011 / Accepted: 9 November 2011 / Published: 18 November 2011
Cited by 2 | PDF Full-text (531 KB) | HTML Full-text | XML Full-text
Abstract
Like any other drug, antimicrobial drugs are prone to pharmacokinetic drug interactions. These drug interactions are a major concern in clinical practice as they may have an effect on efficacy and toxicity. This article provides an overview of all published pharmacokinetic studies [...] Read more.
Like any other drug, antimicrobial drugs are prone to pharmacokinetic drug interactions. These drug interactions are a major concern in clinical practice as they may have an effect on efficacy and toxicity. This article provides an overview of all published pharmacokinetic studies on drug interactions of the commonly prescribed antimicrobial drugs oxazolidinones, rifamycines, macrolides, fluoroquinolones, and beta-lactams, focusing on systematic research. We describe drug-food and drug-drug interaction studies in humans, affecting antimicrobial drugs as well as concomitantly administered drugs. Since knowledge about mechanisms is of paramount importance for adequate management of drug interactions, the most plausible underlying mechanism of the drug interaction is provided when available. This overview can be used in daily practice to support the management of pharmacokinetic drug interactions of antimicrobial drugs. Full article
(This article belongs to the Special Issue Drug Interactions of Antimicrobial Agents)
Open AccessReview Antiretroviral Drug Interactions: Overview of Interactions Involving New and Investigational Agents and the Role of Therapeutic Drug Monitoring for Management
Pharmaceutics 2011, 3(4), 745-781; doi:10.3390/pharmaceutics3040745
Received: 5 August 2011 / Revised: 15 September 2011 / Accepted: 8 October 2011 / Published: 21 October 2011
Cited by 10 | PDF Full-text (302 KB) | HTML Full-text | XML Full-text
Abstract
Antiretrovirals are prone to drug-drug and drug-food interactions that can result in subtherapeutic or supratherapeutic concentrations. Interactions between antiretrovirals and medications for other diseases are common due to shared metabolism through cytochrome P450 (CYP450) and uridine diphosphate glucuronosyltransferase (UGT) enzymes and transport [...] Read more.
Antiretrovirals are prone to drug-drug and drug-food interactions that can result in subtherapeutic or supratherapeutic concentrations. Interactions between antiretrovirals and medications for other diseases are common due to shared metabolism through cytochrome P450 (CYP450) and uridine diphosphate glucuronosyltransferase (UGT) enzymes and transport by membrane proteins (e.g., p-glycoprotein, organic anion-transporting polypeptide). The clinical significance of antiretroviral drug interactions is reviewed, with a focus on new and investigational agents. An overview of the mechanistic basis for drug interactions and the effect of individual antiretrovirals on CYP450 and UGT isoforms are provided. Interactions between antiretrovirals and medications for other co-morbidities are summarized. The role of therapeutic drug monitoring in the detection and management of antiretroviral drug interactions is also briefly discussed. Full article
(This article belongs to the Special Issue Drug Interactions of Antimicrobial Agents)
Figures

Journal Contact

MDPI AG
Pharmaceutics Editorial Office
St. Alban-Anlage 66, 4052 Basel, Switzerland
pharmaceutics@mdpi.com
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18
Editorial Board
Contact Details Submit to Pharmaceutics
Back to Top